JNJ Jun 2025 90.000 put
| Previous close | 0.4700 |
| Open | 0.4700 |
| Bid | 0.0000 |
| Ask | 1.8000 |
| Strike | 90.00 |
| Expiry date | 2025-06-20 |
| Day's range | 0.4700 - 0.4700 |
| Contract range | N/A |
| Volume | |
| Open interest | 48 |
PR NewswireCARVYKTI® (ciltacabtagene autoleucel) achieved statistically significant and clinically meaningful improvement in overall survival in landmark CARTITUDE-4 study
Johnson & Johnson (NYSE:JNJ) announced today positive results from a prespecified second interim analysis of the Phase 3 CARTITUDE-4 study evaluating CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd) for the treatment of patients with relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy. The interim analysis showed a statistically
ZacksMerck (MRK) Gets CHMP Nod for PAH Drug Winrevair in Europe
Merck's (MRK) Winrevair is poised to become the first activin signaling inhibitor therapy for PAH in Europe if approved by the European Commission.
- Yahoo Finance Video
How Medicare drug price negotiations could hit pharma stocks
As a string of negative headlines and promising new developments present ideal buying opportunities for investors, Josh Lipton and Julie Hyman perform a mid-year check on the pharmaceutical industry. Goldman Sachs senior biotechnology analyst Chris Shibutani joins Market Domination to break down the health of the pharmaceutical large-caps and unrecognized areas of opportunity in the sector. Shibutani says the industry is "quite healthy," but acknowledges there are always "cross currents." He points to "tremendous advancements" in biotechnology innovation rising to daunting unmet needs, from cancer to cardiovascular disease. The analyst points to "holy grail-like" opportunities such as obesity drugs, and notes improvements in chemotherapy and next-generation antibody-drug conjugates for cancer treatment. However, Shibutani explains that the Inflation Reduction Act may challenge the industry, as the landmark legislation stipulates drug price negotiation for Medicare that is "beginning to play out." For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This article was written by Gabriel Roy
